MeSH tree: D12.776.124.790.651.114.224.060
The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to cheaper alternatives.
Nov 1, 2025
0
40
Retinal vein occlusion (RVO) is one of the leading causes of vision loss worldwide, often triggered by chronic diseases such as hypertension and diabetes. Similar to a blocked water pipe causing backflow and pressure buildup, ...
Oct 29, 2025
0
12
Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern suggesting" a lower five-year risk of any first cancer (excluding non-melanoma skin cancer) with ustekinumab ...
For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England Journal of Medicine to coincide ...
Oct 21, 2025
0
13
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat ...
Oct 20, 2025
0
10
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with ...
Oct 20, 2025
0
14
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating multiple sclerosis.
Sep 25, 2025
0
22
New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses ...
Sep 23, 2025
0
15
People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult ...
Sep 8, 2025
0
26
Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage ...
Sep 8, 2025
0
19
